Related Experiment Videos
Comparative in vitro activity of cefpiramide, a new parenteral cephalosporin
Abstract:
The in vitro activity of cefpiramide was compared with that of nine other cephalosporins by determining the MIC values by means of an agar dilution method for 300 representative clinical isolates of nonfastidious bacteria. Cefpiramide had a broad-spectrum of activity, similar to that of the third-generation cephalosporins. As judged by the MIC50 and the MIC90 values, cefpiramide was one of the most active cephalosporins against Pseudomonas aeruginosa (MIC50 2.9 micrograms/ml, MIC90 64 micrograms/ml), staphylococci (MIC50 1.2 micrograms/ml, MIC90 10 micrograms/ml) and Enterococcus faecalis (MIC50 13 micrograms/ml, MIC90 43 micrograms/ml). Cefpiramide had moderate activity against Enterobacteriaceae (MIC50 4 micrograms/ml, MIC90 108 micrograms/ml), comparable to that of the older second-generation cephalosporins. Ticarcillin-resistant strains of gram-negative rods were inhibited by higher concentrations of cefpiramide than ticarcillin-susceptible strains.
Insights
Cefpiramide exhibits broad-spectrum antimicrobial activity, showing potent efficacy against Pseudomonas aeruginosa, staphylococci, and Enterococcus faecalis. Its activity against Enterobacteriaceae is comparable to older cephalosporins.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Antibiotic resistance is a growing global health concern.
- Cephalosporins are a critical class of beta-lactam antibiotics used to treat bacterial infections.
- Evaluating novel cephalosporins like cefpiramide is essential for combating resistant pathogens.
Purpose of the Study:
- To compare the in vitro antibacterial activity of cefpiramide against other cephalosporins.
- To determine the minimum inhibitory concentration (MIC) values for cefpiramide against a diverse range of clinical bacterial isolates.
- To assess cefpiramide's efficacy against specific challenging pathogens, including Pseudomonas aeruginosa and staphylococci.
Main Methods:
- Agar dilution method was employed to determine MIC values.
- 300 representative clinical isolates of nonfastidious bacteria were tested.
- Cefpiramide's activity was compared against nine other cephalosporins.
Main Results:
- Cefpiramide demonstrated broad-spectrum activity, comparable to third-generation cephalosporins.
- It showed high potency against Pseudomonas aeruginosa (MIC50 2.9 µg/mL, MIC90 64 µg/mL), staphylococci (MIC50 1.2 µg/mL, MIC90 10 µg/mL), and Enterococcus faecalis (MIC50 13 µg/mL, MIC90 43 µg/mL).
- Activity against Enterobacteriaceae was moderate (MIC50 4 µg/mL, MIC90 108 µg/mL), similar to older second-generation cephalosporins. Ticarcillin-resistant Gram-negative rods required higher cefpiramide concentrations for inhibition.
Conclusions:
- Cefpiramide possesses significant in vitro activity against key Gram-positive and Gram-negative bacteria, including challenging pathogens.
- Its profile suggests potential utility in treating infections caused by susceptible organisms.
- Further clinical evaluation is warranted to establish cefpiramide's therapeutic role.